46.77
-1.20%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Betta Pharmaceuticals Co
Its shares trade on Shenzhen under the ticker 300558.SZ. It has been listed since 7 November 2016. In the fiscal year to 31 December 2025, it reported revenue of CN¥3.61bn and net income of CN¥305.3m. At that date it held total assets of CN¥10.57bn and shareholders' equity of CN¥6.60bn.
Betta Pharmaceuticals Co., Ltd. engages in the research and development, production, and sale of anticancer targeted drugs. The company is headquartered in Hangzhou, Zhejiang. The company went IPO on 2016-11-07. The firm's primary product is its self-developed icotinib hydrochloride (Conmana), a small molecule targeted anticancer drug used for the treatment of lung cancer. The firm is also engaged in promotional services, real estate leasing and other businesses.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 7 Nov 2016
- Employees
- 1,961
- Website
- bettapharma.com ↗
Leadership
Pay as last reported
- Mr. Lieming DingChairman of the Board, Chief Executive Officer, General Manager, since 2013CN¥2.7m
- Mr. Jianxun FanChief Financial Officer, Vice President, Director, since 2016CN¥1.3m
- Ms. Jia TongPresident - Public Administration, Director, since 2013CN¥1.3m
- Mr. Li MaoPresident - R&D, Chief Medical Officer, since 2019CN¥249,900
- Mr. Jiang WanChief Operating Officer, Senior Vice President, Director, since 2013CN¥2.4m
- Mr. Lingxi WuSecretary of the BoardCN¥918,000
- Mr. Shizhe DingDirectorCN¥228,000
- Mr. Tian XuDirector
- Mr. Zhihua YuDirector
- Mr. Jiangnan CaiIndependent DirectorCN¥120,000
- Ms. Xinqi HuangIndependent DirectorCN¥120,000
- Mr. Wei WangIndependent DirectorCN¥120,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 53
- Environment
- 49
- Social
- 39
- Governance
- 69
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Betta Pharmaceuticals Co Ltd has a self-developed product icotinib hydrochloride (Conmana) for lung cancer treatment.
- The company is headquartered in Hangzhou, Zhejiang, with 1961 employees in the Health Care sector.
- Betta Pharmaceuticals Co Ltd has an IPO listing date of November 7, 2016.
Weaknesses
- Betta Pharmaceuticals Co Ltd operates primarily in the Pharmaceuticals industry within China (CN).
- The company's product line is limited to icotinib hydrochloride (Conmana) as its primary anticancer drug.
- Betta Pharmaceuticals Co Ltd has a single headquarters city, Hangzhou, which may limit regional diversification.
Opportunities
- Betta Pharmaceuticals Co Ltd can expand its promotional services within the Health Care sector.
- The company may leverage its real estate leasing business to generate additional revenue streams.
- Betta Pharmaceuticals Co Ltd could explore new markets for its anticancer targeted drugs beyond China.
Threats
- Betta Pharmaceuticals Co Ltd faces competition in the Pharmaceuticals industry for anticancer drugs.
- The company's reliance on a single product, icotinib hydrochloride (Conmana), poses a market risk.
- Betta Pharmaceuticals Co Ltd's operations in Hangzhou, Zhejiang, may be affected by regional economic fluctuations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.